Pde1c Antibody

What is PDE1C and why is it significant in cardiovascular research?

PDE1C is a calmodulin-dependent cyclic nucleotide phosphodiesterase with dual specificity for the second messengers cAMP and cGMP. It plays a crucial role in cardiac remodeling and dysfunction, as evidenced by its upregulation in both human and mouse failing hearts . PDE1C regulates protective cAMP/PKA signaling pathways in cardiac myocytes that antagonize myocyte death and hypertrophic growth. Studies have demonstrated that PDE1C deficiency or inhibition attenuates cardiac remodeling and dysfunction by counteracting cardiac myocyte hypertrophy and death as well as cardiac fibroblast activation . Therefore, PDE1C represents a potential therapeutic target for heart failure treatment.

How do I select the appropriate PDE1C antibody for my specific research application?

Selection should be based on several key parameters:

For instance, the antibody 13785-1-AP shows reactivity with human and mouse samples for WB, IP, and ELISA applications . Always verify antibody specificity using appropriate controls, such as PDE1C knockout tissues as demonstrated in multiple studies .

What is the molecular weight and structure of PDE1C protein that antibodies should detect?

PDE1C has a calculated molecular weight of 72 kDa (634 amino acids) and is typically observed at approximately 68 kDa on Western blots . The protein functions as a homodimer and contains calcium/calmodulin binding domains that regulate its enzymatic activity . When selecting antibodies, note that there are multiple isoforms of PDE1C generated by alternative splicing, including PDE1C1, PDE1C2, and PDE1C3 . Some antibodies, such as that from FabGennix, are designed to label all PDE1C variants . The protein's structure includes catalytic domains responsible for cyclic nucleotide hydrolysis and regulatory domains that mediate calcium/calmodulin binding and activation.

What are the optimal conditions for using PDE1C antibodies in Western blot applications?

Based on published protocols:

For optimal results, prepare tissue lysates in buffers containing protease inhibitors and phosphatase inhibitors such as Na₃VO₄ and okadaic acid, as described in PDE assay protocols . When analyzing PDE1C expression changes in disease models, include appropriate controls and normalize to housekeeping proteins.

How can I effectively use PDE1C antibodies for immunohistochemistry (IHC) of cardiovascular tissues?

For successful IHC staining of PDE1C in cardiovascular tissues:

• Tissue preparation: Use formalin-fixed, paraffin-embedded (FFPE) sections of heart or aortic tissue.

• Antigen retrieval: Heat-mediated antigen retrieval in citrate buffer (pH 6.0) is typically effective.

• Blocking: Block with 5-10% normal serum from the species of the secondary antibody.

• Primary antibody: Apply PDE1C antibody at dilutions of 1:40-1:100 or 1:500 for heart tissues .

• Detection system: Use appropriate HRP/DAB or fluorescent detection systems.

• Controls: Include PDE1C knockout tissues as negative controls. Research shows that PDE1C antibody specificity can be validated using AAA sections from PDE1C⁻/⁻ApoE⁻/⁻ mice .

Immunofluorescent staining has successfully revealed PDE1C expression in SMC-like cells of human AAA wall and in cardiac myocytes . PDE1C expression is notably absent in cardiac fibroblasts, making this a useful negative control .

What is the best approach for measuring PDE1C activity in tissue samples?

For measuring PDE1C-specific enzymatic activity:

• Tissue preparation: Collect fresh ventricular tissue, flash freeze, and lyse in PDE assay buffer containing 40 mM Tris-HCl (pH 7.5), 1 mM EDTA, 15 mM β-mercaptoethanol, 20% glycerol, and protease/phosphatase inhibitors .

• Assay conditions:

  • Use 1 μM cAMP substrate with trace ³H-cAMP

  • Perform parallel reactions with:
    a) 1 mM EGTA (Ca²⁺/CaM-independent activity)
    b) 4 μg/mL calmodulin and 0.8 mM CaCl₂ (Ca²⁺/CaM-dependent activity)

• Specific PDE1C activity calculation:

  • Total PDE activity = percentage total minus background

  • PDE1-specific activity = (total activity with Ca²⁺/CaM) - (activity with PDE1 inhibitor)

  • Normalize to protein concentration

• Inhibitor controls: Use IC86340 (15 μM) as a PDE1-specific inhibitor, along with other selective inhibitors for PDE families to confirm specificity .

This radiolabeled nucleotide method has been established and validated in multiple studies for measuring PDE1C activity in cardiovascular tissues .

How can PDE1C antibodies be utilized to study the role of PDE1C in pathological cardiac remodeling?

Advanced applications include:

• Temporal expression analysis: Use PDE1C antibodies to track changes in protein expression during disease progression. Studies have shown that PDE1C expression is upregulated in mouse TAC hearts relative to sham-operated hearts, as well as in tissue from failing human hearts compared to heart tissue from healthy donors .

• Cell-type specific expression: Immunofluorescence co-staining with PDE1C antibodies and cell-type markers (αSMA for smooth muscle cells, cTnT for cardiomyocytes) can reveal that PDE1C is highly expressed in cardiac myocytes but has negligible expression in fibroblasts .

• Mechanistic studies: Combine PDE1C antibodies with phospho-specific antibodies targeting downstream effectors (PKA substrates, AKT phosphorylation) to delineate signaling pathways. Research has revealed that in cardiac myocytes, PDE1C negatively regulates protective cAMP/PKA signaling, and activation of PI3K/AKT appears necessary for mediating the protective effects of PDE1C depletion on cell death .

• Potential therapeutic evaluation: Use PDE1C antibodies to validate target engagement of PDE1 inhibitors in preclinical models. Current development of pan-PDE1 inhibitors for treating schizophrenia suggests the potential safety of these compounds, which may be repurposed for cardiac remodeling and failure .

What approaches can be used to study PDE1C involvement in smooth muscle cell proliferation and vascular pathologies?

Sophisticated experimental approaches include:

• Proliferation assays with genetic manipulation:

  • Use PDE1C antibodies to confirm expression changes after antisense oligonucleotide treatment. Studies have used phosphothioate PDE1C antisense oligonucleotides (sequence: ACTCGATACCTCAGCGG) to inhibit PDE1C expression in human SMCs .

• In vivo disease models:

  • Employ PDE1C antibodies for immunofluorescent staining of abdominal aortic aneurysm (AAA) tissues. Research has demonstrated PDE1C induction in SMC-like cells in human and mouse AAA lesions .

  • Use PDE1C knockout mouse models (PDE1C⁻/⁻ApoE⁻/⁻) to study the causative role of PDE1C in AAA development .

• Mechanistic investigations:

  • Combine with senescence markers to study the relationship between PDE1C and SMC senescence. PDE1C-controlled cAMP has been shown to suppress SMC senescence through cAMP-mediated direct interaction and activation of SIRT1 .

• Therapeutic validation:

  • Use PDE1C antibodies to confirm target engagement of pharmacological PDE1 inhibitors like IC86340, which has been shown to attenuate AAA progression of preexisting moderate AAA in mice .

How can I design experiments to investigate the interactions between PDE1C and calcium/calmodulin signaling?

Design sophisticated experiments to explore this regulatory mechanism:

• Calcium-dependent activity assays:

  • Measure PDE1C enzymatic activity under varying calcium concentrations to establish calcium-response curves.

  • Compare activities with and without calmodulin to determine the calcium-calmodulin enhancement factor.

• Co-immunoprecipitation studies:

  • Use PDE1C antibodies (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate ) to pull down PDE1C and associated proteins.

  • Probe for calmodulin binding under varying calcium concentrations.

  • Analyze additional interacting proteins that may regulate PDE1C-calmodulin interactions.

• Structural analysis:

  • Implement proximity ligation assays to visualize PDE1C-calmodulin interactions in situ.

  • Use PDE1C antibodies that target different domains to map the calmodulin-binding regions of PDE1C.

• Live-cell imaging:

  • Combine PDE1C immunofluorescence with calcium imaging to correlate calcium fluctuations with PDE1C localization and activity in cardiomyocytes or smooth muscle cells.

These approaches will help elucidate how calcium/calmodulin regulation of PDE1C contributes to its function in cyclic nucleotide signaling pathways.

What are common challenges when using PDE1C antibodies, and how can they be addressed?

Common issues and solutions include:

For optimal results, verify the specificity of your PDE1C antibody using PDE1C knockout tissues or cells. Several studies have shown that PDE1C antibody specificity can be confirmed using negative controls performed in mouse and human AAA sections and in AAA of PDE1C⁻/⁻ApoE⁻/⁻ mice .

How do I distinguish between PDE1C isoforms and other PDE family members in my experiments?

Differentiating between closely related PDE family members requires careful experimental design:

• Isoform-specific antibody selection:

  • Choose antibodies raised against unique regions of PDE1C. For example, the FabGennix antibody targets a synthetic peptide corresponding to a unique amino acid sequence within region 1-50 of PDE1C .

  • Verify the antibody does not cross-react with PDE1A, PDE1B, or other PDE family members.

• Expression pattern analysis:

  • PDE1C is highly expressed in cardiac myocytes but negligible in fibroblasts .

  • PDE1C is expressed in proliferating human SMCs but absent in quiescent human aorta .

  • PDE1C shows distinct tissue distribution: expressed in brain, heart, lung, and testis tissues .

• Molecular weight discrimination:

  • PDE1C has an observed molecular weight of approximately 68 kDa .

  • Compare with other PDE family members that have different molecular weights.

• Functional validation:

  • Use specific PDE1 inhibitors like IC86340 (15 μM) in combination with antibody detection.

  • Complement antibody studies with PDE activity assays that can distinguish between different PDE families through selective inhibitors.

What considerations are important when using PDE1C antibodies for co-localization studies with other signaling proteins?

For successful co-localization experiments:

• Primary antibody compatibility:

  • Ensure PDE1C antibody and other target antibodies are raised in different host species to avoid cross-reactivity of secondary antibodies.

  • If using multiple rabbit antibodies, consider direct conjugation of one antibody or sequential staining protocols.

• Fixation and permeabilization optimization:

  • Different fixatives (PFA, methanol) may preserve certain epitopes while masking others.

  • Test multiple fixation conditions to optimize detection of all targets.

• Signal amplification strategies:

  • For low-abundance proteins, consider tyramide signal amplification or other amplification methods.

  • Balance amplification with maintaining spatial resolution.

• Controls for co-localization:

  • Include positive controls (proteins known to interact with PDE1C).

  • Include negative controls (proteins not expected to co-localize).

  • Perform quantitative co-localization analysis using appropriate software and metrics.

• Subcellular compartment markers:

  • Include markers for relevant subcellular compartments (cytoplasm, membrane, etc.).

  • PDE1C is primarily cytosolic , but its localization may change under different cellular conditions.

How might PDE1C antibodies be utilized to validate potential therapeutic targeting of PDE1C?

Antibody-based validation approaches include:

• Target engagement verification:

  • Use PDE1C antibodies to confirm binding of PDE1 inhibitors to PDE1C in tissue samples after in vivo administration.

  • Perform immunoprecipitation with PDE1C antibodies followed by detection of bound inhibitors.

• Expression pattern characterization:

  • Map PDE1C expression in normal versus pathological states to identify optimal therapeutic windows.

  • Studies have shown PDE1C expression is upregulated in failing hearts and in smooth muscle cells during proliferation .

• Functional consequences assessment:

  • Use PDE1C antibodies alongside phospho-specific antibodies to monitor downstream signaling changes after PDE1 inhibitor treatment.

  • Key pathways to monitor include cAMP/PKA signaling, PI3K/AKT activation, and SIRT1 activation .

• Combinatorial therapeutic approaches:

  • Investigate potential synergistic effects of PDE1 inhibitors with other cardiovascular drugs.

  • Current development of pan-PDE1 inhibitors like ITI-214 for heart failure (under clinical trial phase 2) suggests that PDE1 inhibition may be a viable therapeutic strategy.

What emerging research areas might benefit from PDE1C antibody applications?

Novel research directions include:

• Age-related cardiovascular pathologies:

  • Investigate the relationship between PDE1C expression and cellular senescence in cardiovascular aging.

  • PDE1C-controlled cAMP has been shown to suppress SMC senescence through SIRT1 activation .

• Metabolic regulation in cardiac disease:

  • Explore connections between PDE1C activity and cardiac energy metabolism.

  • Study how cyclic nucleotide regulation by PDE1C affects metabolic pathways in cardiomyocytes.

• Cardiac regeneration:

  • Investigate PDE1C expression and function in cardiac progenitor cells.

  • Determine if PDE1C inhibition could promote cardiac repair after injury.

• Personalized medicine approaches:

  • Use PDE1C antibodies to stratify patient samples based on PDE1C expression levels.

  • Correlate PDE1C expression patterns with disease progression and response to therapies.

• Cross-talk with other signaling pathways:

  • Explore how PDE1C interacts with non-canonical signaling pathways beyond cAMP/cGMP.

  • Investigate potential regulation by microRNAs or epigenetic mechanisms.

How can PDE1C antibodies be used to study its role in cardiac myocyte-fibroblast crosstalk?

Advanced approaches to study intercellular communication include:

• Conditioned media experiments:

  • Use PDE1C antibodies to confirm PDE1C expression in cardiac myocytes but not in fibroblasts.

  • Research has shown that conditioned medium from PDE1C-deficient cardiac myocytes attenuated TGF-β-stimulated cardiac fibroblast activation .

• Co-culture systems:

  • Establish co-culture models of cardiac myocytes and fibroblasts.

  • Use PDE1C antibodies with cell-type-specific markers to track expression changes during cell-cell communication.

• Secretome analysis:

  • Immunoprecipitate PDE1C from cardiac myocytes to identify associated secreted factors.

  • Compare the secretome of wild-type versus PDE1C-deficient cardiac myocytes.

• In vivo cell-type-specific analysis:

  • Employ PDE1C antibodies for multiplexed immunohistochemistry to analyze spatial relationships between cardiac myocytes and fibroblasts in heart failure models.

  • Correlate PDE1C expression with markers of fibrosis and myocyte stress in tissue sections.

These approaches will help elucidate how PDE1C in cardiac myocytes regulates the production of secreted factors important for fibroblast activation and fibrosis, despite PDE1C not being expressed in fibroblasts themselves .